Lupin Limited (IN:LUPIN)
:LUPIN
Want to see IN:LUPIN full AI Analyst Report?
LUPIN Stock Chart & Stats
₹1938.85
-₹105.50(-4.47%)
At close: 4:00 PM EST
₹1938.85
-₹105.50(-4.47%)
Day’s Range― - ―
52-Week Range₹1,838.65 - ₹2,492.00
Previous CloseN/A
Volume1.35M
Average Volume (3M)25.39K
Market Cap
₹1.04T
Enterprise Value₹1.05T
Total Cash (Recent Filing)₹62.82B
Total Debt (Recent Filing)₹62.17B
Price to Earnings (P/E)19.8
Beta0.58
Next Earnings
Aug 11, 2026EPS Estimate
28.93Next Dividend Ex-DateN/A
Dividend Yield0.57%
Share Statistics
EPS (TTM)94.74
Shares Outstanding457,215,850
10 Day Avg. Volume23,417
30 Day Avg. Volume25,387
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)4.71
Price to Sales (P/S)3.78
P/FCF Ratio20.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)100.15
Revenue Forecast (FY)₹294.88B
Bulls Say, Bears Say
Bulls Say
Margin ImprovementLupin's shift from losses to robust profitability (net margin 19.07%, EBIT 24.67% in 2026) indicates durable earnings power from better pricing, cost control and higher-value mix. Sustained margins support reinvestment, R&D and resilience through generic cycles.
Revenue Recovery And GrowthAccelerating revenue growth (12.96% in 2026) reflects successful product launches, market share gains and stronger demand across domestic and international segments. A multi-year top-line recovery underpins economies of scale and supports long-term margin sustainability.
Improved Cash GenerationA sharp free cash flow rebound (+120.48% in 2026) and doubling of operating cashflow materially strengthen Lupin's ability to fund capex, opportunistic M&A or debt repayment. Improved cash conversion, even if inconsistent historically, enhances financial flexibility over coming quarters.
Bears Say
Gross Margin VolatilityFluctuating gross margins suggest exposure to product-mix shifts, pricing pressure in commoditized generics and input-cost variability. Persistent volatility can erode predictability of profits, complicate budgeting and weaken the durability of recent margin gains if higher-margin launches slow.
Inconsistent Cash ConversionWhile 2026 FCF improved, multi-year inconsistent cash conversion (FCF/NI ~0.71, prior weak years) points to working-capital swings or timing effects. That reduces reliability of internal funding and can force external financing or defer investments during adverse quarters.
Rising Debt In Most Recent YearAn uptick in debt in 2026, despite overall moderate leverage, reduces headroom if industry or margin pressures re-emerge. Higher interest/service obligations and less balance-sheet flexibility could constrain capital allocation and elevate risk during a downturn or slower revenue growth.
Lupin Limited News
LUPIN FAQ
What was Lupin Limited’s price range in the past 12 months?
Lupin Limited lowest stock price was ₹1838.65 and its highest was ₹2492.00 in the past 12 months.
What is Lupin Limited’s market cap?
Lupin Limited’s market cap is ₹1.04T.
When is Lupin Limited’s upcoming earnings report date?
Lupin Limited’s upcoming earnings report date is Aug 11, 2026 which is in 82 days.
How were Lupin Limited’s earnings last quarter?
Lupin Limited released its earnings results on May 07, 2026. The company reported ₹34.75 earnings per share for the quarter, beating the consensus estimate of ₹26.503 by ₹8.247.
Is Lupin Limited overvalued?
According to Wall Street analysts Lupin Limited’s price is currently Overvalued.
Does Lupin Limited pay dividends?
Lupin Limited pays a Annually dividend of ₹12 which represents an annual dividend yield of 0.57%. See more information on Lupin Limited dividends here
What is Lupin Limited’s EPS estimate?
Lupin Limited’s EPS estimate is 28.93.
How many shares outstanding does Lupin Limited have?
Lupin Limited has 457,215,850 shares outstanding.
What happened to Lupin Limited’s price movement after its last earnings report?
Lupin Limited reported an EPS of ₹34.75 in its last earnings report, beating expectations of ₹26.503. Following the earnings report the stock price went up 0.712%.
Which hedge fund is a major shareholder of Lupin Limited?
Currently, no hedge funds are holding shares in IN:LUPIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lupin Limited
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Mankind Pharma Ltd.
―
Sun Pharmaceutical Industries Limited
―
Zydus Lifesciences Limited
―